Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use
  • Acronyms BE HEARD II
  • Sponsors UCB Biopharma

Most Recent Events

  • 09 Jun 2026 According to an UCB media release, based on results from BE HEARD I and BE HEARD II trials Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse BIMZELX for the treatment of adults living with moderate to severe hidradenitis suppurativa (HS) with an inadequate response to conventional systemic therapy.
  • 04 Feb 2026 According to an UCB media release, This data will be presented at the 15th Conference of the European Hidradenitis Suppurativa Foundation (EHSF).
  • 04 Feb 2026 Results published in the Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top